Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
BRIEF COMMUNICATION
Year : 2016  |  Volume : 12  |  Issue : 2  |  Page : 1084-1087

Off-label use of Sorafenib in patients with advanced thyroid carcinoma: Retrospective analysis of five cases


Endocrinology Service, Portuguese Institute of Oncology Francisco Gentil EPE; NOVA Medical School/NOVA Medical School, Lisbon, Portugal

Correspondence Address:
Maria Joćo Bugalho
Endocrinology Service, Portuguese Institute of Oncology Francisco Gentil EPE, Rua Professor Lima Basto, Lisboa - 1099 - 023
Portugal
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.154011

Rights and Permissions

We present results obtained in five patients with advanced thyroid cancer, derived from the follicular epithelium, treated with Sorafenib used off-label. The median age at the time Sorafenib was started was 61 years. Only one patient tolerated the standard dose of 400 mg twice daily. The most severe adverse events were:


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1707    
    Printed28    
    Emailed0    
    PDF Downloaded118    
    Comments [Add]    

Recommend this journal